The oligomer modulator anle138b is effective in the prodromal phase of a 
transgenic mouse model of Parkinson's disease.

Prix, C.; Schmidt, F.; Levin, J.; Schinke, K.; Shi, S.; Ryazanov, S.; Leonov, A.; Högen, T.; Mitteregger-Kretzschmar, G.; Kretzschmar, H. A.; Bötzel, K.; Griesinger, C.; Giese, A.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Conference Paper

The oligomer modulator anle138b is effective in the prodromal phase of a transgenic mouse model of Parkinson's disease.

MPS-Authors

/persons/resource/persons45923

Ryazanov, S.
Department of NMR Based Structural Biology, MPI for biophysical chemistry, Max Planck Society;

/persons/resource/persons15438

Leonov, A.
Department of NMR Based Structural Biology, MPI for biophysical chemistry, Max Planck Society;

/persons/resource/persons15147

Griesinger, C.
Department of NMR Based Structural Biology, MPI for biophysical chemistry, Max Planck Society;

External Resource

http://onlinelibrary.wiley.com/doi/10.1111/ene.12496/pdf
(Publisher version)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Prix, C., Schmidt, F., Levin, J., Schinke, K., Shi, S., Ryazanov, S., et al. (2014). The oligomer modulator anle138b is effective in the prodromal phase of a transgenic mouse model of Parkinson's disease. European Journal of Neurology, 21(Suppl. 1), 170-170.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0019-F61D-A

Abstract

There is no abstract available